结构性心脏病干预后的抗血栓治疗:当前状况和未来方向
Andreas Mitsis1, Michaela Kyriakou1, Evi Christodoulou2
1Cardiology Department, Nicosia General Hospital, 2029 Nicosia, Cyprus.
Reviews in cardiovascular medicine
|July 30, 2024
概括
抗血栓治疗对于预防通过导管结构性心脏病干预后的并发症至关重要. 根据特定的程序和患者因素量身定制治疗优化了结果.
科学领域:
- 心脏病学 心脏病学
- 干预心脏病学 干预心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 基于导管的干预措施解决各种先天性和获得性结构性心脏病.
- 常见的程序包括门植入/修复和隔膜缺陷关闭.
- 抗血栓治疗对于预防干预后的血栓栓塞事件至关重要.
研究的目的:
- 对结构性心脏干预的抗血栓策略的现有证据进行审查.
- 强调个性化抗血栓治疗方法的必要性.
- 为指导医疗保健专业人员管理抗血栓治疗.
主要方法:
- 对当代证据的系统审查.
- 在跨导管结构性心脏病干预中对抗血栓治疗的分析.
- 综合考虑程序类型和患者因素的数据.
主要成果:
- 抗血栓治疗选择因干预类型和患者特征而有所不同.
- 个人化方法被强调为管理风险的关键.
- 证据支持量身定制治疗以尽量减少短期和长期并发症.
结论:
- 个性化抗血栓治疗对于结构性心脏干预至关重要.
- 医疗保健专业人员必须随时了解不断变化的指南.
- 个性化治疗计划可以改善患者的治疗结果并减少并发症.
相关概念视频
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
505
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
505
Anticoagulant Drugs: Low-Molecular-Weight Heparins
659
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
659
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
413
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
413
Cardiovascular Drugs: Classification based on Therapeutic Indications
2.2K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
2.2K
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.3K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.3K


